These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 12455303)

  • 21. Aromatase inhibitors in the treatment of breast cancer.
    Brueggemeier RW; Hackett JC; Diaz-Cruz ES
    Endocr Rev; 2005 May; 26(3):331-45. PubMed ID: 15814851
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Exemestane, a new steroidal aromatase inhibitor of clinical relevance.
    Lombardi P
    Biochim Biophys Acta; 2002 Jul; 1587(2-3):326-37. PubMed ID: 12084475
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT.
    Chia S; Gradishar W; Mauriac L; Bines J; Amant F; Federico M; Fein L; Romieu G; Buzdar A; Robertson JF; Brufsky A; Possinger K; Rennie P; Sapunar F; Lowe E; Piccart M
    J Clin Oncol; 2008 Apr; 26(10):1664-70. PubMed ID: 18316794
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Exemestane in advanced breast cancer.
    Buzdar A
    Anticancer Drugs; 2000 Sep; 11(8):609-16. PubMed ID: 11081451
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Exemestane versus anastrozole as front-line endocrine therapy in postmenopausal patients with hormone receptor-positive, advanced breast cancer: final results from the Spanish Breast Cancer Group 2001-03 phase 2 randomized trial.
    Llombart-Cussac A; Ruiz A; Antón A; Barnadas A; Antolín S; Alés-Martínez JE; Alvarez I; Andrés R; García Saenz JA; Lao J; Carrasco E; Cámara C; Casas I; Martín M
    Cancer; 2012 Jan; 118(1):241-7. PubMed ID: 21717449
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Exemestane in breast cancer: current status and future directions.
    Lønning PE
    Clin Breast Cancer; 2000 Sep; 1 Suppl 1():S28-33. PubMed ID: 11970747
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Update on the use of aromatase inhibitors in breast cancer.
    Brueggemeier RW
    Expert Opin Pharmacother; 2006 Oct; 7(14):1919-30. PubMed ID: 17020418
    [TBL] [Abstract][Full Text] [Related]  

  • 28. To switch or not to switch: should the updated Intergroup Exemestane Study alter our decision?
    Iddon J; Bundred NJ
    Expert Rev Anticancer Ther; 2008 Jan; 8(1):9-13. PubMed ID: 18095878
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aromatase inhibitors in the breast cancer clinic: focus on exemestane.
    Van Asten K; Neven P; Lintermans A; Wildiers H; Paridaens R
    Endocr Relat Cancer; 2014 Feb; 21(1):R31-49. PubMed ID: 24434719
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Endocrine and clinical endpoints of exemestane as neoadjuvant therapy.
    Miller WR; Dixon JM
    Cancer Control; 2002; 9(2 Suppl):9-15. PubMed ID: 11965226
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nonsteroidal and steroidal aromatase inhibitors in breast cancer.
    Hamilton A; Volm M
    Oncology (Williston Park); 2001 Aug; 15(8):965-72; discussion 972, 977-9. PubMed ID: 11548977
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Network Meta-Analysis Comparing Overall Survival for Fulvestrant 500 mg Versus Alternative Therapies for Treatment of Postmenopausal, Estrogen Receptor-Positive Advanced Breast Cancer Following Failure on Prior Endocrine Therapy.
    Telford C; Jones N; Livings C; Batson S
    Clin Breast Cancer; 2016 Jun; 16(3):188-95. PubMed ID: 26971303
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Systematic review of aromatase inhibitors in the first-line treatment for hormone sensitive advanced or metastatic breast cancer.
    Riemsma R; Forbes CA; Kessels A; Lykopoulos K; Amonkar MM; Rea DW; Kleijnen J
    Breast Cancer Res Treat; 2010 Aug; 123(1):9-24. PubMed ID: 20535542
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane.
    Buzdar AU; Robertson JF; Eiermann W; Nabholtz JM
    Cancer; 2002 Nov; 95(9):2006-16. PubMed ID: 12404296
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-aromatase agents in the treatment and prevention of breast cancer.
    Goss P
    Cancer Control; 2002; 9(2 Suppl):2-8. PubMed ID: 11965225
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Exemestane as first-line therapy in postmenopausal women with recurrent or metastatic breast cancer.
    Glück S
    Am J Clin Oncol; 2010 Jun; 33(3):314-9. PubMed ID: 19730353
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Overview of the pharmacology of the aromatase inactivator exemestane.
    Brueggemeier RW
    Breast Cancer Res Treat; 2002 Jul; 74(2):177-85. PubMed ID: 12186378
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of obesity on the efficacy of exemestane plus ovarian suppression in hormone receptor-positive premenopausal breast cancer.
    Şendur MA; Aksoy S; Akıncı MB; Ozdemir N; Dede DŞ; Altundag K; Zengin N; Yalçın B
    Future Oncol; 2015; 11(6):905-7. PubMed ID: 25760972
    [No Abstract]   [Full Text] [Related]  

  • 39. Effects of exemestane and tamoxifen in a postmenopausal breast cancer model.
    Jelovac D; Macedo L; Handratta V; Long BJ; Goloubeva OG; Ingle JN; Brodie AM
    Clin Cancer Res; 2004 Nov; 10(21):7375-81. PubMed ID: 15534114
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Approval summary: letrozole in the treatment of postmenopausal women with advanced breast cancer.
    Cohen MH; Johnson JR; Li N; Chen G; Pazdur R
    Clin Cancer Res; 2002 Mar; 8(3):665-9. PubMed ID: 11895893
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.